Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Raymond James Maintains Strong Buy on DexCom, Raises Price Target to $160

Author: Benzinga Newsdesk | April 26, 2024 01:32pm
Raymond James analyst Jayson Bedford maintains DexCom (NASDAQ:DXCM) with a Strong Buy and raises the price target from $151 to $160.

Posted In: DXCM

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist